|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.7645 - 0.8375|
|52 Week Range||0.5400 - 3.6210|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Canadian cannabis producer looks for even stronger growth in the future thanks to its increased production capacity and entrance into new markets.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) is pleased to provide a corporate update and report its Second Quarter 2019 financial results for the period ended June 30, 2019. Aleafia Health has filed its consolidated financial statements and related management’s discussion and analysis, both of which are available on Aleafia Health’s profile at www.SEDAR.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. “The foundation that our team has built over the last year is now beginning to prove its worth as we report marked improvements with record revenue generated, significant cost reductions and a growing base of active, registered medical cannabis patients,” said Aleafia Health CEO Geoffrey Benic.
Aleafia Health (ALEAF) is a little cannabis company that has legitimate growth potential; something many of its smaller peers, in reality, actually don't.The major catalysts that could propel the company to the next level is its facilities that are close to being licensed by Health Canada, and its recent acquisition of Emblem Cannabis Corporation, which is giving it more options and results than it was capable of before the deal.While the company has a lot to do and prove before I would be a believer, it has positioned itself to give it a chance to become a potential growth company with a future.Latest earningsIn the first quarter the company generated $1.5 million in revenue, up over 1,700 percent from the $0.1 million generated in the same reporting period a year ago.The company had a net loss of $20.2 million in the quarter, with an adjusted net loss of $7 million after excluding one-time, non-cash payments of $13.2 million associated with the closing of the acquisition of Emblem.It had $36.8 million in cash on its balance sheet at the end of March 2019, and total assets were at $61 million, including cash.Licensing getting closer to full approvalLicensing approval for Port Perry Outdoor Grow and Niagara Greenhouse moving along nicely.The Port Perry Outdoor Grow includes 1.1 million square feet of space, or approximately 26 acres. That's the same area its Port Perry Indoor facility is located. Aleafia said it finished the build-out of the site and on May 3 submitted its evidence package to Health Canada showing it meets all requirements to receive its License Amendment. It is currently under review.At the Port Perry Outdoor Grow facility it has already been approved for Zone 2, and has 13,000 plants currently growing at that location.The company also stated it has received a status update back from Health Canada concerning its 160,000 square foot Niagara Greenhouse facility, saying it had passed a high-level review, and so far there were no concerns communicated by Health Canada concerning the facility.It appears it won't be long before Aleafia receives both licenses, barring some unforeseen issue that needs to be fixed. Either way, I would be surprised if Aleafia doesn't get approved for both licenses soon.What Else Emblem Cannabis brings to the tableThe acquisition of Emblem Cannabis Corporation is a real potential game changer for Aleafia in a number of ways. First, it brings immediate revenue growth to the table, and has already entered into the biggest deal Aleafia has ever made.It reported that Emblem completed an adult-use cannabis order which is expected to generate sales exceeding $1 million, which has already been sent to a Canadian provincial government for online and physical retail distribution.Aleafia Health CEO Geoffrey Benic said closing the acquisition of Emblem will accelerate its "global mission of growing, processing and selling high-margin value-added cannabis products by 12 to 18 months.”Leveraging its growth facilities across Emblem's larger footprint should also boost growth going forward.On the global level, Emblem adds exposure to the important German market via its joint venture with German pharmaceutical wholesaler and logistics company Acnos Pharma GmbH.Aleafia now owns 60 percent of the joint venture, which includes access to about 20,000 pharmacies and 110 distribution centers.Outside of Emblem, Aleafia also has a 10 percent stake in Australian Licensed Producer CannaPacific Pty. Limited.The company already has received an Import Permit from the Australian Office of Drug Control, and has applied to Health Canada for an export permit.Emblem also has a top Canadian medical cannabis clinic that has seen 60,000 patients.ConclusionIf Aleafia successfully obtains its licenses and permits, and executes well in its production facilities once they're operational, it has positioned itself to go through a period of significant growth.The acquisition of Emblem has really upped the game for Aleafia, and if it manages to leverage the strengths of Emblem efficiently, it should surprise a lot of investors that don't pay much if any attention to the small cannabis company.There are no real guarantees with Aleafia Health, but among companies of its size or a little larger, it appears to have one of the stronger chances at achieving success. It's definitely worth watching closely.See Gary Bourgeault's stock picks on TipRanks
TORONTO, Aug. 07, 2019 -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) will announce its 2019 Second Quarter Financial Results on.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) is announcing that its wholly owned subsidiary, Emblem Cannabis Corporation, has completed the largest adult-use cannabis order (the “Order”) in the Company’s history. The value of the Order is expected to generate proceeds from the sale of cannabis exceeding $1.0 million, and has been shipped to a Canadian provincial government for distribution to online and retail consumers. The single Order features all of the Company’s product formats and 17 individual product SKUs.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) is pleased to announce that on July 12, 2019, Aleafia Health’s wholly-owned subsidiary, Aleafia Farms Inc., secured a License Amendment (the “Licence”) under Health Canada’s Cannabis Regulations authorizing cannabis cultivation for the entirety of the Company’s Port Perry Outdoor Grow facility. The Licence immediately increases the Company’s licensed and operational outdoor cultivation area from 292,000 sq. ft. to over 1.1 million sq. ft. As previously announced on June 10, 2019, Aleafia Farms received approval for cultivation in Zone 1 of the Outdoor Grow facility, and days later completed the planting of Canada’s first legal, large-scale outdoor crop.
TORONTO, July 11, 2019 -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has been added to The Cannabis ETF (NYSE: THCX) (“THCX”),.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has received multiple Export Permits (the “Permits”) from Health Canada, which allow the Company to begin its first international cannabis product shipment. The Company expects to ship its branded medical cannabis oils in the next month, which will be distributed by Australian Licensed Producer CannaPacific Pty. Limited (“CannaPacific”).
Cannabis stocks rose Thursday, led by Aleafia Health Inc., which rallied after announcing the closure of a $40. 25 million convertible debt offering that will bolster its balance sheet and help grow its business.
TORONTO, June 27, 2019 (GLOBE NEWSWIRE) -- (ALEF.TO) (ALEAF) (ARAH.F) Aleafia Health Inc. (“Aleafia Health” or the “Company”) is pleased to announce that it has closed its previously announced public offering of convertible debenture units (the “Convertible Debenture Units”) of the Company at a price of $1,000 per Convertible Debenture Unit for aggregate gross proceeds of $40,250,000 (the “Offering”), which includes the full exercise of the over-allotment option. The Offering was led by Mackie Research Capital Corporation and BMO Capital Markets, and included Canaccord Genuity Corp. (together, the “Agents”).
Aleafia Health Inc. (the “Company”) (ALEF.TO) (OTC: ALEAF) (ARAH.F) is pleased to announce the results of the vote on the election of directors at its annual and special meeting of shareholders held on June 17, 2019 (the “Meeting”). On a vote conducted by ballot, all seven nominees set out in the management information circular of the Company dated May 10, 2019 were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. The voting results based on the ballots cast are set out below. Final voting results on all matters voted on at the Meeting have been filed with the Canadian securities regulators on the Company’s SEDAR profile at www.sedar.com.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has completed the planting of its first outdoor crop, less than one week after securing Health Canada approval for outdoor cultivation. To the Company’s knowledge, Aleafia Health is the first licensed producer to complete a large-scale, legal outdoor crop in Canadian history.
In its short history, Aleafia Health (ALEAF) has went through several periods of rapid increase in its share price, and not too long afterwards, a rapid decline in its share price.After plunging from around $2.40 per share in the latter part of September 2018, Aleafia Health plunged to about $0.94 per share, finally finishing 2018 at close to $1.03 per share. From then until mid-February 2019, it once again jumped, this time to a double top of $1.94, before once again reversing direction, losing all its gains on the year, falling to $1.00 as I write.With a triple bottom of about $1.00 per share since the beginning of the year, it's apparent if Aleafia drops below the $1.00 mark, it's almost certain to plummet below what it's floor has been since the beginning of the year. On the other hand, if it once again manages to hold at that level, we'll probably see it take another upward run.The major reason for the extreme volatility in the stock, beyond being in a volatile sector at this time, is because it has yet to secure enough domestic and international supply agreements to provide a more visible, predictable performance. It also needs to complete its current expansion projects that will boost production capacity.The Emblem dealOne of the more significant positive catalysts for Aleafia has been the acquisition of Emblem, which now combined, should be able to produce up to 138,000 kilograms annually. It also increased the number of medical clinics they control to 40, which together have served 60,000 medical patients.On the positive side, Aleafia has quietly built itself to be one of the top-10 leaders in cannabis production. Its strong exposure to medical cannabis patients also provides it with the capability of generating wider margins than if it was solely exposed to the recreational pot market. Included in its product portfolio are sprays, capsules and oils.What I think the market is waiting for with Aleafia is for it to prove it can effectively and efficiently scale out its operations in domestic and international markets.Global expansionWhile Aleafia has some strength in the Canadian medical cannabis market, it has been slow to make any meaningful headway in the international markets. That may change with the closing of the acquisition of Emblem.Included with the Emblem acquisition was a joint venture with German-based Acnos Pharma GmbH, which it has a 60 percent stake in. Recently Aleafia stated it was going to leverage its supply chain network via its partnership into the German medical cannabis market. Acnos Pharma GmbH has access to 110 distribution centers and 20,000 pharmacies in the German market.Another part of its international growth strategy is in Australia, where it closed its 10 percent equity stake in CannaPacific Pty. Limited, a licensed producer in that country.Aleafia has been granted an import permit from the Australian Office of Drug Control, and has applied for an export permit from Health Canada. Once it receives the expected approval, the company will deliver its first shipment to an international market.ConclusionAleafia Health continues to struggle because it has yet to prove it can execute on what appears to be a potentially profitable business model.The issue of having to wait for its production facilities to be completed and for some of its permits to be approved in different markets, makes it hard for the company to retain any sustainable momentum.Its exposure to the Canadian medical cannabis market is fairly solid, but there is enormous competition there. The company, again, has to prove it can compete against its larger competitors and peers.Even though the company may soon export its first medical cannabis, management has said it will take about 12 to 18 months before things start to really take off on that front.If Aleafia was saying all these things about a year ago, I would be more positive on the company, but as it stands, it does have potential, and I wouldn't be surprised to see it enjoy another round of serious upward trajectory for its share price, but I don't see it having anything sustainable at this time that would help it to support that level.For that reason, I look at Aleafia as being better for a trade rather thinking in terms of taking a long-term position in the company.It does have a clear vision and potential pathway to success, but it has yet to prove it can execute its plan. Until it does, this is going to remain a very volatile stock that could test the recent lower end of its support at about $1.03 per share.If the company does deliver on its promises, it could enjoy a prolonged period of support on the upper end of its potential, generating nice returns for shareholders. It'll probably take at least a year before we start to get more clarity on that potential outcome.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Marijuana Stock Supreme Cannabis Is Ready to Spark Higher * Is the Surge in Nvidia (NVDA) Stock Sustainable? Merrill Lynch Sees Further Upside Ahead * Qualcomm (QCOM) Stock Has Limited Upside, Says UBS * Can Baidu (BIDU) Stock Keep Going After This Week’s Pop?
Company’s Licensed Cultivation Area Increases from 22,000 sq. ft. to 314,000 sq. ft. TORONTO, June 10, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has been granted approval by Health Canada for outdoor cannabis cultivation.
Aleafia Health Inc. (“Aleafia Health” or the “Company”) (ALEF.TO) (ALEAF) (ARAH.F) is pleased to report that its offering, previously announced on June 5, 2019, (the “Offering”) will be for an offering size of $35,000,000. The Offering will be conducted on an agency basis for the issuance of 35,000 convertible debenture units of the Company (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit (the “Offering Price”).
NEW YORK , June 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index ...
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) is pleased to provide a corporate update and report its First Quarter 2019 financial results for the period ended March 31, 2019. Aleafia Health has filed today its consolidated financial statements and related management’s discussion and analysis, both of which are available on Aleafia Health’s profile at www.SEDAR.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. The Company’s acquisition of Emblem Corp. (“Emblem”) closed on March 14, 2019, and as a result, Emblem financial results prior to the closing date are not reported in the financial statements.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has completed the largest adult-use cannabis order (the “Order”) in the Company’s history today. The Order is scheduled to depart from the Company’s facility today, with delivery to a Canadian provincial government for distribution to online and retail consumers. It will contain the Company’s branded Symbl oils, oral sprays and dried flower products.
Aleafia Health Inc.’s (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) Board of Directors have approved an advance notice by‑law, the purpose of which is to require that advance notice be provided to the Company in circumstances in which nominations of persons for election to the Board are made by shareholders other than pursuant to the requisition of a meeting or a shareholder proposal in accordance with the Business Corporations Act (Ontario) (the “Advance Notice By-law”). The Advance Notice By‑law fixes a deadline by which shareholders must provide notice to the Company of nominations for election to the Board, and sets out the information that a shareholder must include in the notice for it to be valid.
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) is entering the German medical cannabis market via its joint-venture (the “JV”) with German pharmaceutical wholesaler Acnos Pharma GmbH (“Acnos”), together (the “Parties”). The JV entity will purchase Aleafia Health branded cannabis oils for distribution to German pharmacies and for clinical trial usage.